TY - JOUR
T1 - Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome
AU - Klinger, G.
AU - Frankenthal, D.
AU - Merlob, P.
AU - Diamond, G.
AU - Sirota, L.
AU - Levinson-Castiel, R.
AU - Linder, N.
AU - Stahl, B.
AU - Inbar, D.
N1 - Funding Information:
The study was supported by research grants from the Department of Neurology and the Neonatal Intensive Care Unit, Schneider Children’s Medical Center of Israel. We thank Mrs Pearl Lilos, MSc, of the Department of Statistics, Tel Aviv University, for excellent statistical analysis. We also acknowledge the work and dedication of the pediatric psychologists: Salam Amer, MSc, and Bossmat Aronson, MSc, of the Neurology Department, Schneider Children’s Medical Center of Israel.
PY - 2011/9
Y1 - 2011/9
N2 - Objective: To assess the long-term neurodevelopment of children exposed in utero to selective serotonin reuptake inhibitors (SSRIs) that developed a neonatal abstinence syndrome (NAS). Study Design: Neurodevelopmental evaluation was performed at the age of 2 to 6 years. Children who developed NAS were compared with those who did not using univariate and logistic regression analyses. Result: Thirty children with NAS and 52 without NAS participated in the study. Both groups were similar in mean cognitive ability (106.9±14.0 vs 100.5±14.6, P=0.12) and developmental scores (98.9±11.4 vs 95.7±9.9, P=0.21). However, there was a trend towards small head circumference in the NAS group (20 vs 6%, P=0.068). NAS was associated with an increased risk of social-behavior abnormalities (odds ratio (OR) 3.03, 95% confidence interval (CI) 1.07 to 8.60, P=0.04) and advanced maternal age (OR 1.12, 95% CI 1.00 to 1.25, P=0.04). Conclusion: Infants who developed NAS had normal cognitive ability, but were at an increased risk for social-behavioral abnormalities. Follow-up evaluation of symptomatic neonates should be considered.
AB - Objective: To assess the long-term neurodevelopment of children exposed in utero to selective serotonin reuptake inhibitors (SSRIs) that developed a neonatal abstinence syndrome (NAS). Study Design: Neurodevelopmental evaluation was performed at the age of 2 to 6 years. Children who developed NAS were compared with those who did not using univariate and logistic regression analyses. Result: Thirty children with NAS and 52 without NAS participated in the study. Both groups were similar in mean cognitive ability (106.9±14.0 vs 100.5±14.6, P=0.12) and developmental scores (98.9±11.4 vs 95.7±9.9, P=0.21). However, there was a trend towards small head circumference in the NAS group (20 vs 6%, P=0.068). NAS was associated with an increased risk of social-behavior abnormalities (odds ratio (OR) 3.03, 95% confidence interval (CI) 1.07 to 8.60, P=0.04) and advanced maternal age (OR 1.12, 95% CI 1.00 to 1.25, P=0.04). Conclusion: Infants who developed NAS had normal cognitive ability, but were at an increased risk for social-behavioral abnormalities. Follow-up evaluation of symptomatic neonates should be considered.
KW - long-term outcome
KW - neonatal abstinence syndrome
KW - selective serotonin reuptake inhibitor
UR - http://www.scopus.com/inward/record.url?scp=80052386238&partnerID=8YFLogxK
U2 - 10.1038/jp.2010.211
DO - 10.1038/jp.2010.211
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:80052386238
SN - 0743-8346
VL - 31
SP - 615
EP - 620
JO - Journal of Perinatology
JF - Journal of Perinatology
IS - 9
ER -